Galectin-3 in the Progression and Metastasis of Colorectal Neoplasia

Galectins

Volumn , Issue , 2008, Pages 193-221

  Byrd, James C ^a   Bresalier, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colon cancer mucin galectin 3 interaction; Colorectal neoplasia galectin 3 metastasis; Galectin 3 Ser6 phosphorylation

Indexed keywords

EID: 84889830424     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470378076.ch10     Document Type: Chapter

References (101)

1. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactosebinding lectin correlates with neoplastic progression in the colon. Cancer 1995;75: 2818-2826.
2. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, Raz A. Metastasis of human colon cancer is altered by modifying expression of the betagalactoside- binding protein galectin-3. Gastroenterology 1998;115:287-296.
3. Holt PR, Bresalier RS, Ma CK, Liu KF, Lipkin M, Byrd JC, Yang K. Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa. Cancer 2006;106:287-296.
4. Bresalier RS, Byrd JC, Wang L, Raz A. Colon cancer mucin: a new ligand for the betagalactoside- binding protein galectin-3. Cancer Res 1996;56:4354-4357.
5. Mazurek N, Conklin J, Byrd JC, Raz A, Bresalier RS. Phosphorylation of the betagalactoside- binding protein galectin-3 modulates binding to its ligands. J Biol Chem 2000;275:36311-36315.
6. Dudas SP, Yunker CK, Sternberg LR, Byrd JC, Bresalier RS. Expression of human intestinal mucin is modulated by the beta-galactoside binding protein galectin-3 in colon cancer. Gastroenterology 2002;123:817-826.
7. Song S, Byrd JC, Mazurek N, Liu K, Koo JS, Bresalier RS. Galectin-3 modulates MUC2 mucin expression in human colon cancer cells at the level of transcription via AP-1 activation. Gastroenterology 2005;129:1581-1591.
8. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, Raz A. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 1999;59:6239-6245.
9. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, Bresalier RS, Raz A. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004;24:4395-4406.
10. Mazurek N, Sun YJ, Price JE, Ramdas L, SchoberW, Nangia-Makker P, Byrd JC, Raz A, Bresalier RS. Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes. Cancer Res 2005;65:10767-10775.
11. Mazurek N, Sun YJ, Liu KF, Gilcrease MZ, Schober W, Nangia-Makker P, Raz A, Bresalier RS. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J Biol Chem 2007;282: 21337-21348.
12. Bresalier RS, Byrd JC, Tessler D, Lebel J, Koomen J, Hawke D, Half E, Liu KF, Mazurek N. A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer. Gastroenterology 2004;127:741-748.
13. Liu K, Byrd JC, Song S, Bresalier RS. Expression of galectin-3 and its binding protein (Mac-2-BP) correlate with progression and metastasis of colorectal adenocarcinoma. Gastroenterology 2006;130:A88.
14. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002;94:1854-1862.
15. Cooper DNW. Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002;1572:209-231.
16. Lotz MM, Andrews CW, Korzelius CA, Lee EC, Steele, Clarke A, Mercurio AM. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 1993;90:3466-3470.
17. Sanjuan X, Fernandez PL, Casells A, Casronovo V, van den Brule FA, Liu FT, Cardesa A, Campo E. Differential expression of galectin-3 and galectin-1 in colorectal cancer progression. Gastroenterology 1997;113:1906-1915.
18. Ochieng J, Platt D, Tait L, Hogan V, Raz T, Carmi P, Raz A. Structure-function relationship of a recombinant human galactoside-binding protein. Biochemistry 1993; 32:4455-4460.
19. Raz A, Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 1987;6: 433-452.
20. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000;156: 899-909.
21. Yu F, Finley Jr RL, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002;277:15819-15827.
22. Irimura T, Matsushita Y, Sutton RC, Carralero D, Ohannesian DW, Cleary KR, Ota DM, Nicolson GL, Lotan R. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 1991;51: 387-393.
23. Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector JC, Salmon I, Yeaton P, Gabius HJ, Kiss R, Camby I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 2003;103:370-379.
24. Inufusa H, Nakamura M, Adachi T, Aga M, Kurimoto M, Nakatani Y,Wakano T, Miyake M, Okuno K, Shiozaki H, Yasutomi M. Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol 2001;19:913-919.
25. Bresalier RS, Hujanen ES, Raper SE, Roll FJ, Itzkowitz SH, Martin GR, Kim YS. An animal model for colon cancer metastasis. Establishment and characterization of murine colon cancer cell lines with enhanced liver-metastazing ability. Cancer Res 1985;47: 249-260.
26. Bresalier RS, Raper SE, Hujanen ES, Kim YS. A new animal model for human colon cancer metastasis. Int J Cancer 1987;39:625-630.
27. Bresalier RS, Rockwell RW, Dahiya R, Duh Q-Y, Kim YS. Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis. Cancer Res 1990;50:1299-1307.
28. Bresalier RS, Niv Y, Byrd JC, Duh Q, Toribara NW, Kim YS. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 1991;87:1037-1045.
29. Qi Y, Moyana T, Matte G, Wilkinson A, Bresalier RS, Xiang J. Immunolocalization of hepatic metastases of human colonic cancer by chimeric anti-AG72 antibody in SCID mice. J Surg Oncol 1995;8:3-9.
30. Qi Y, Moyana T, Bresalier RS, Xiang J. Antibody targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice. Gastroenterology 1995;109:1950-1957.
31. Bresalier RS, Schwartz B, Kim YS, Duh Q-Y, Kleinman HK, Sullam PM. The laminin (a1 chain Ile-Lys-Val-Ala-Val (IKVA)-containing peptide promotes liver colonization by human colon cancer cells. Cancer Res 1995;55:2476-2480.
32. Sternberg LR, Byrd JC, Yunker CK, Dudas S, Hoon V, Bresalier RS. Liver colonization by human colon cancer cells is reduced by antisense inhibition of MUC2 mucin synthesis. Gastroenterology 1999;116:363-371.
33. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-99.
34. Bresalier RS. Intestinal mucin and colon cancer. Gastroenterology 2002;123:648-649.
35. Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 2006;1765:189-222.
36. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.
37. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 1996;49:560-564.
38. Matsuda K, Masaki T, Watanabe T, Kitayama J, Nagawa H, Muto T, Ajioka Y. Clinical significance of MUC1 and MUC2 mucin and p53 protein expression in colorectal carcinoma. Jpn J Clin Oncol 2000;30:89-94.
39. Ogata S, Uehara H, Chen A, Itzkowitz SH. Mucin gene expression in colonic tissues and cell lines. Cancer Res 1992;52:5971-5978.
40. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim YS. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-651.
41. Allen A, Hutton DA, Pearson JP. The MUC2 gene product: a human intestinal mucin. Int J Biochem Cell Boil 1998;7:797-801.
42. Chang SK, Dohrman AF, Basbaum CB, Ho SB, Tsuda T, ToribaraNW, Gum JR, Kim YS. Localisation of mucin (MUC2 and MUC3) mRNA and peptide expression in normal human intestine and colon cancer. Gastroenterology 1994;107:160-172.
43. Weiss AA, Babyatsky MW, Ogata S, Chen A, Itzkowitz SH. Expression of MUC2 and MUC3 mRNA in human normal, malignant and inflammatory tissues. J Histochem Cytochem 1996;44:1161-1166.
44. Sylvester PA, Myerscough N, Warren BF, Carlstedt I, Corfield AP, Durdey P, Thomas MG. Differential expression of the chromosome 11 mucin genes in colorectal cancer. J Pathol 2001;195:327-335.
45. Blank M, Klussman E, Kruger-Krasagakes S, Schmitt-Graff A, Stolte M, Bornhoeft G, Stein H, Xing PX, McKenzie IFC, Verstijnen CPHJ, Riecken EO, Hanski CJ. Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. Int J Cancer 1994;59:301-306.
46. Biemer-Huttmann AE, Walsh MD, McGuckin MA, Simms LA, Young J, Leggett BA, Jass JR. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res 2000;6:1909-1916.
47. Manne U, Weiss HL, Grizzle WE. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. Clin Cancer Res 2000;6:4017-4025.
48. Velcich A, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L. Colorectal cancer in mice genetically deficient in the mucin MUC2. Science 2002;295:1726-1729.
49. Schwartz B, Bresalier RS, Kim YS. Role of mucin in colon cancer metastasis. Int J Cancer 1992;52:60-65.
50. Bresalier RS, Ho SB, Schoeppner HL, Kim YS, Sleisenger MH, Brodt P, Byrd JC. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 1996;110:1354-1367.
51. Brodt P, Fallavollita L, Bresalier RS, Norton CR, Wolitzky BA. E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 1997;71:612-614.
52. Bresalier RS, Byrd JC, Brodt P, Ogata S, Yunker C. Liver metastasis and adhesion to the sinusoidal endothelium by human colon cancer cells is related to mucin carbohydrate chain length. Int J Cancer 1998;76:556-562.
53. Sternberg LR, Byrd JC, Yunker CK, Hansson GC, Liu K-F, Bresalier RS. Alternative splicing of the human MUC2 gene. Arch Biochem Biophys 2004;421:21-33.
54. Huflejt ME, Turck CW, Lindstedt R, Barondes SH, Leffler H. L-29, a soluble lactosebinding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. J Biol Chem 1993;268:26712-26718.
55. Hamann KK, Cowles EA, Wang JL, Anderson RL. Expression of carbohydrate binding protein 35 in human fibroblasts variations in the levels of mRNA, protein, and isoelectric species as a function of replicative competence. Exp Cell Res 1991;196:82-91.
56. Cowles EA, Agrwal N, Anderson RL, Wang JL. Carbohydrate-binding protein 35. Isoelectric points of the polypeptide and a phosphorylated derivative. J Biol Chem 1990;265:17706-17712.
57. Pienta KJ, Naik H, Akhtar A, Yamazaki K, Repogle TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995;87:348-353.
58. Yoshi T, Fukumori T, Honjo Y, Inohara H, Kim HRC, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002;277:6852-6857.
59. Henrick K, Bawumia S, Barboni EAM, Hughes RC. Evidence for subsites in the galectins involved in sugar binding at the non-reducing end of the central galactose of oligosaccharide ligands: sequence analysis, homology modeling and mutagenesis studies of hamster galectin-3. Glycobiology 1998;8:45-57.
60. Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal domain in selfassociation of galectin-3. Biochemistry 1998;37:4086-4092.
61. Kim HRC, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999;59:4148-4154.
62. Nakahara S, Hogan V, Inohara H, Raz A. Importin-mediated nuclear translocation of galectin-3. J Biol Chem 2006;281:39649-39659.
63. Davidson PJ, Li SY, Lohse AG, Vandergaast R, Verde E, Pearson A, Patterson RJ, Wang JL, Arnoys EJ. Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import. Glycobiology 2006;16:602-611.
64. Song S, Byrd JC, Koo JS, Bresalier RS. Bile acids induce MUC2 overexpression in human colon carcinoma cells. Cancer 2005;103:1606-1614.
65. Li JD, Feng WJ, Gallup MG, Gum J, Kim Y, Basbaum C. Activation of NF-kappa-B via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosainduced mucin overproduction in epithelial cells. Proc Natl Acad Sci USA 1998;95: 5718-5723.
66. Jono H, Shuto T, Xu H, Kai H, Lim DJ, Gum JR, Kim JS, Yamaoka S, Feng XH, Li JD. Transforming growth factor-beta-Smad signaling pathway cooperates with NF-kappa B to mediate nontypeable Haemophilus influenzae-induced MUC2 mucin transcription. J Biol Chem 2002;277:45547-45557.
67. Aslam F, Palumbo L, Augenlicht LH, Velcich A. The Sp family of transcription factors in the regulation of the human and mouse MUC2 gene promoters. Cancer Res 2001;61: 570-576.
68. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002;277:32258-32267.
69. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 2003;300:813-818.
70. Patterson RJ,WangW,Wang JL. Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus. Glycoconj J 2004;19:499-506.
71. Shiura T, Takenaka Y, Fukumorio T, Tsutsumi S, Okada K, Hogan V, Kikuchi A, Kuwano H, Raz A. Implication of galectin-3 in Wnt signaling. Cancer Res 2005;65:3535-3537.
72. Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T, Raz A. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 2005;65:7546-7553.
73. Paron I, Scaloni A, Pines A, Bachi A, Liu F-T, Puppin C, Pandolfi M, Ledda L, Di Loretto C, Danante G, Tell G. Nuclear localization of galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 2003;302:545-553.
74. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997;57:5272-5276.
75. Choi JH, Chun KH, Raz A, Lotan R. Inhibition of N-(4-hydroxyphenyl)retinamideinduced apoptosis in breast cancer cells by galectin-3. Cancer Biol Ther 2004;3:447-452.
76. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002;277:6852-6857.
77. Sarafian V, Jadot M, Foidart JM, Letesson JJ, Van den Brule F, Castonovo V,Wattiaux R, Wattiaux-De Coninck S. Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. Int J Cancer 1998;75:105-111.
78. Inohara H, Raz A. Identification of human cellular and secreted ligands for galectin-3. Biochem Biophys Res Commun 1994;201:1366-1375.
79. Ohhannesian DW, Lotan D, Thomas P, Jessup JM, Fukuda M, Gabius HG, Lotan R. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 1995;55:2191-2199.
80. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 2003;268: 14245-14249.
81. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 2001;27:3595-3602.
82. Hikita C, Vijayakumar S, Takit J, Erdjument-Bromage H, Tempst P, Al-Awqati Q. Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin-3. J Cell Biol 2000;151:1235-1246.
83. Frigeri LG, Liu FT. Surface expression of functional IgE binding protein, an endogenous lectin, on mast cells and macrophages. J Immunol 1992;148:861-867.
84. Cortegano I, del Pozo V, Cardaba B, Arrieta I, Gallardo S, Rojo M, Aceituno E, Takai T, Verbeek S, Palomino P, Liu FT, Lahoz C. Interaction between galectin-3 and FcgRII induces down-regulation of IL-5 gene: implication of the promoter sequence IL-5REIII. Glycobiology 2000;10:237-242.
85. Crider-Pirkle S, Bilingsle P, Faust C, Hardy DM, Lee V, Weitlauf H. Cubulin, a binding partner for galectin-3 in the murine utero-placental complex. J Biol Chem 2002;277:15904-15912.
86. Henrick K, Bawumia S, Barboni EAM, Mehul B, Hughes RC. Evidence for subsites in the galectins involved in sugar binding at the nonreducing end of the central galactose of oligosaccharide ligands: sequence analysis, homology modeling and mutagenesis studies of hamster galectin-3. Glycobiology 1998;8:45-47.
87. Ideo H, Seko A, Ohkura T, Matta KL, Yamashita K. High-affinity binding of recombinant human galectin-4 to SO3-3Gal-GalNAc pyranoside. Glycobiology 2002;12:199-208.
88. Goletz S, Hanisch FG, Karsten U. Novel GalNAc containing glycans on cytokeratins are recognized in vitro by galectins with type II carbohydrate recognition domains. J Cell Sci 1997;110:1585-1596.
89. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 2005;7:522-527.
90. Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 1992;84:438-442.
91. Inohara H, Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 1994;11:527-532.
92. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996;93:6737-6742.
93. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997;57:5272-5276.
94. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, MalorniW, Iacobelli S. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000;85:545-554.
95. Hayashi A, Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modified citrus pectin. Altern Med Rev 2000;5:546-552.
96. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005;65:8350-8358.
97. McCarty MF and Block KI. Toward a core nutraceutical program for cancer management. Integr Cancer Ther 2006;5:150-171.
98. Sathisha UV, Jayaram S, Nayaka MAH, Dharmesh SM. Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources. Glycoconj J 2007;24:497-507.
99. Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D'Egidio M, Piccolo E, Tinari N, Nifantiev N, Iacobelli S. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006;16:210-220.
100. Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 2005;26:309-318.
101. André S, Maljaars CE, Halkes KM, Gabius HJ, Kamerling JP. Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett 2007;17:793-798.